Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism

Cardiovascular Research

Volumn 69, Issue 1, 2006, Pages 218-226

  Eligini, Sonia ^a   Violi, Francesco ^c   Banfi, Cristina ^b   Barbieri, Silvia S ^a   Brambilla, Marta ^b   Saliola, Mirella ^c   Tremoli, Elena ^a,b   Colli, Susanna ^a  

^a Center E Grossi Paoletti   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c POLICLINICO UMBERTO I   (Italy)

Author keywords

Indobufen; Monocytes; Thrombosis; Thromboxane; Tissue factor

Indexed keywords

INDOBUFEN;

ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE ACTIVATION; WESTERN BLOTTING;

CELLS, CULTURED; CYCLOOXYGENASE INHIBITORS; DEPRESSION, CHEMICAL; DINOPROSTONE; FLOW CYTOMETRY; HUMANS; LIPOPOLYSACCHARIDES; MONOCYTES; PHENYLBUTYRATES; THROMBOPLASTIN; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANES;

EID: 29144452461     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2005.07.013     Document Type: Article

References (58)

1. V. Tamassia, G. Corvi, L.M. Fuccella, E. Moro, G. Tosolini, and E. Tremoli Indobufen (K 3920), a new inhibitor of platelet aggregation: effect of food on bioavailability, pharmacokinetic and pharmacodynamic study during repeated oral administration to man Eur J Clin Pharmacol 15 1979 329 333
2. M. Cattaneo, C. Bevilacqua, A. Lecchi, and P.M. Mannucci In vitro and ex vivo effects of indobufen on human platelet aggregation, the release reaction and thromboxane B2 production Haemostasis 17 1987 293 300
3. L. Mannucci, P. Maderna, S. Colli, M. Lavezzari, C.R. Sirtori, and E. Tremoli Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk Thromb Res 48 1987 417 426
4. The SINBA Group Indobufen versus aspirin plus dipyridamole after coronary bypass surgery Coron Artery Dis 2 1991 897 906
5. G. Cataldo, M. Braga, N. Pirotta, M. Lavezzari, F. Rovelli, and E. Marubini Factors influencing 1-year patency of coronary artery saphenous vein grafts. Studio indobufene nel bypass aortocoronarico (SINBA) Circulation 88 1993 93 98
6. S.M. Rajah, U. Nair, M. Rees, N. Saunders, D. Walker, and G. Williams Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting J Thorac Cardiovasc Surg 107 1994 1146 1153
7. C. Pratesi, R. Pulli, G. Milanesi, M. Lavezzari, F. Pamparana, and D. Bertini Indobufen versus placebo in the prevention of restenosis after carotid endarterectomy: a double-blind pilot study J Int Med Res 19 1991 202 209
8. G. Fornaro, P. Rossi, P.G. Mantica, M.E. Caccia, D. Aralda, and M. Lavezzari Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study Circulation 87 1993 162 164
9. B. Girolami, E. Bernardi, M.H. Prins, J.W. ten Cate, P. Prandoni, and R. Hettiarachchi Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis Thromb Haemost 81 1999 715 722
10. M. Chello, P. Mastroroberto, V. Celi, F. Romano, A.R. Marchese, and A. Colonna Reduction by indobufen of neutrophil activation in peripheral arterial occlusive disease J Cardiovasc Pharmacol 27 1996 417 423
11. C. Morocutti, G. Amabile, F. Fattapposta, A. Nicolosi, S. Matteoli, and M. Trappolini Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators Stroke 28 1997 1015 1021
12. F. Cipollone, P. Patrignani, A. Greco, M.R. Panara, R. Padovano, and F. Cuccurullo Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina Circulation 96 1997 1109 1116
13. T.S. Edgington, N. Mackman, K. Brand, and W. Ruf The structural biology of expression and function of tissue factor Thromb Haemost 66 1991 67 79
14. S.D. Carson, and J.P. Brozna The role of tissue factor in the production of thrombin Blood Coagulation and Fibrinolysis 4 1993 281 292
15. S.I. Rapaport, and L.V. Rao Initiation and regulation of tissue factor-dependent blood coagulation Arterioscler Thromb 12 1992 1111 1121
16. M. Levi, T. van der Poll, and H.R. Büller Bidirectional relation between inflammation and coagulation Circulation 109 2004 2698 2704
17. E. Tremoli, M. Camera, V. Toschi, and S. Colli Tissue factor in atherosclerosis Atherosclerosis 144 1999 273 283
18. P. Libby, and D.I. Simon Inflammation and thrombosis: the clot thickens Circulation 103 2001 1718 1720
19. D. Ardissino, P.A. Merlini, K.A. Bauer, E. Bramucci, M. Ferrario, and R. Coppola Thrombogenic potential of human coronary atherosclerotic plaque Blood 98 2001 2726 2729
20. O. Mizuno, U. Ikeda, Y. Hojo, H. Fujikawa, T. Katsuki, and K. Shimada Tissue factor expression in coronary circulation as a prognostic factor for late restenosis after coronary angioplasty Cardiology 95 2001 84 89
21. A.H.M. Moons, M. Levi, and R.J.G. Peters Tissue factor and coronary artery disease Cardiovasc Res 53 2002 313 325
22. B. Jude, B. Agraou, E.P. McFadden, S. Susen, C. Bauters, and P. Lepelley Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina Circulation 90 1994 1662 1668
23. H. Soejima, H. Ogawa, H. Yasue, K. Kaikita, K. Nishiyama, and K. Misumi Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina Circulation 99 1999 2908 2913
24. W.H. Lee, Y. Lee, J.R. Kim, J.A. Chu, S.Y. Lee, and J.O. Jung Activation of monocytes, T-lymphocytes and plasma inflammatory markers in angina patients Exp Mol Med 31 1999 159 164
25. J.C. Freeburn, J.M. Wallace, J.J. Strain, D.G. Sinnamon, B.M. Craig, and D. Johnson Monocyte tissue factor-like activity in post myocardial infarction patients Br J Haematol 102 1998 605 608
26. M. Ernofsson, S. Thelin, and A. Siegbahn Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study J Thorac Cardiovasc Surg 113 1997 576 584
27. A. Parolari, S. Colli, L. Mussoni, S. Eligini, M. Naliato, and X. Wang Coagulation and fibrinolytic markers in a two-month follow-up of coronary bypass surgery J Thorac Cardiovasc Surg 125 2003 336 343
28. I. Ott, F.J. Neumann, S. Kenngott, M. Gawaz, and A. Schomig Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction Am J Cardiol 82 1998 938 942
29. S. Colli, M. Lalli, P. Risè, L. Mussoni, S. Eligini, and C. Galli Increased thrombogenic potential of human monocyte-derived macrophages spontaneously transformed into foam cells Thromb Haemost 81 1999 576 581
30. S. Colli, S. Eligini, M. Lalli, M. Camera, R. Paoletti, and E. Tremoli Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis Arterioscler Thromb Vasc Biol 17 1997 265 272
31. 2 inhibits tissue factor expression in human macrophages and endothelial cells: evidence for ERK1/2 signaling pathway blockade Thromb Haemost 88 2002 524 532
32. S. Laufer, P. Zechmeister, and T. Klein Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors Inflamm Res 48 1999 133 138
33. C.J. Rieke, A.M. Mulichak, R.M. Garavito, and W.L. Smith The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors J Biol Chem 274 1999 17109 17114
34. N.V. Chandrasekharan, H. Dai, K.L. Roos, N.K. Evanson, J. Tomsik, and T.S. Elton COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression Proc Natl Acad Sci USA 99 2002 13926 13931
35. A.P.B. Dackiw, S. Grinstein, G.F. Brisseau, I.D. McGilvray, A.B. Nathens, and J.A. McGuire The role of tyrosine phosphorylation in lipopolysaccharide- and zymosan-induced procoagulant activity and tissue factor expression in macrophages Infect Immun 65 1997 2362 2370
36. G.M. Savazzi, A. Castiglioni, A. Cavatorta, G. Garini, M. Montanari, and A. Borghetti Effect of age on the pharmacokinetics of indobufen Int J Clin Pharmacol Ther Toxicol 24 1986 265 269
37. N. Bhana, and K.J. McClellan Indobufen. An updated review of its use in the management of atherothrombosis Drugs and Aging 18 2001 369 388
38. 2 receptors J Pharmacol Exp Ther 270 1994 446 452
39. K.E. Eilertsen, and B. Osterud The central role of thromboxane and platelet activating factor receptors in ex vivo regulation of endotoxin-induced monocyte tissue factor activity in human whole blood J Endotoxin Res 8 2002 285 293
40. Y. Cadroy, D. Dupouy, and B. Boneau Arachidonic acid enhances the tissue factor expression of mononuclear cells by the cyclo-oxygenase-1 pathway: beneficial effect of n-3 fatty acids J Immunol 160 1998 6145 6150
41. 2 production in human monocytes: implications for the use of cyclooxygenase inhibitors J Immunol 165 2000 1605 1611
42. 2 synthase activity in platelet free human monocytes Biochim Biophys Acta 8 1215 1994 285 290
43. 2 synthase that acts in concert with cyclooxygenase-2 J Biol Chem 275 2000 32783 32792
44. K.E. Eilertsen, J.O. Olsen, and B. Osterud Ex-vivo regulation of endotoxin-induced tissue factor in whole blood by eicosanoids Blood Coagul Fibrinolysis 14 2003 41 48
45. P. Patrignani, D. Volpi, R. Ferrario, L. Romanzini, M. Di Somma, and C. Patrono Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood Eur J Pharmacol 191 1990 83 88
46. M. Konieczkowski, and V.A. Skrinska Increased synthesis of thromboxane A(2) and expression of procoagulant activity by monocytes in response to arachidonic acid in diabetes mellitus Prostaglandins Leukot Essent Fatty Acids 65 2001 133 138
47. 2 mimetic I-BOP in A7r5 cells Biochem Pharmacol 53 1997 1823 1832
48. M. Guha, M.A. O'Connell, R. Pawlinski, A. Hollis, P. McGovern, and S.-F. Yan Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factorα expression by inducing Elk-1 phosphorylation and Egr-1 expression Blood 98 2001 1429 1439
49. A.J. Chu, Z.-G. Wang, M. Walton, and A. Seto Involvement of MAPK activation in bacterial endotoxin-inducible tissue factor up-regulation in human monocytic THP-1 cells J Surg Res 101 2001 85 90
50. 2 receptor activates mitogen-activated protein kinase via protein kinase C-dependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor J Pharmacol Exp Ther 296 2001 426 433
51. S.M. Miggin, and B.T. Kinsella Regulation of extracellular signal-regulated kinase cascades by alpha- and beta-isoforms of the human thromboxane A(2) receptor Mol Pharmacol 61 2002 817 831
52. C. Gallet, S. Blaie, S. Levy-Toledano, and A. Habib Thromboxane-induced ERK phosphorylation in human aortic smooth muscle cells Adv Exp Med Biol 525 2003 71 73
53. I.D. McGilvray, Z. Lu, A.C. Wei, and O.D. Rotstein MAP-kinase dependent induction of monocytic procoagulant activity by beta2-integrins J Surg Res 80 1998 272 279
54. P.W. Gudewicz, M.B. Frewin, L.A. Heinel, and F.L. Minnear Priming of human monocyte superoxide production and arachidonic acid metabolism by adherence to collagen- and basement membrane-coated surfaces J Leukoc Biol 55 1994 423 429
55. K.E. Eilertsen, and B. Osterud The role of blood cells and their microparticles in blood coagulation Biochem Soc Trans 33 2005 418 422
56. J.H. Erlich, E.M. Boyle, J. Labriola, J.C. Kovacich, R.A. Santucci, and C. Fearns Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation Am J Pathol 157 2000 1849 1862
57. W. Ruf, and M. Riewald Tissue factor-dependent coagulation protease signaling in acute lung injury Crit Care Med 31 2003 S231 S237
58. R.F. Franco, E. de Jonge, P.E. Dekkers, J.J. Timmerman, C.A. Spek, and S.J. van Deventer The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation Blood 96 2000 554 559